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Abstract: Diabetic kidney disease is characterized by persistent albuminuria ( 300 mg/dl 
or  200 μg/min) that is conﬁ  rmed on at least 2 occasions 3 to 6 months apart, with a progressive 
decline in the glomerular ﬁ  ltration rate (GFR), elevated arterial blood pressure, and an increased 
risk for cardiovascular morbidity and mortality. Diabetic kidney disease is the leading cause 
of end stage renal disease (ESRD) prompting investigators to evaluate mechanisms by which 
to slow disease progression. One such mechanism is to block the activity of angiotensin II at 
the receptor site and agents that follow this mechanism are referred to as angiotensin receptor 
blockers (ARB). There is sufﬁ  cient clinical evidence to support that ARB have protective effects 
on kidney function in patients with diabetes and hypertension. However, in the past decade there 
have been few investigations comparing individual ARBs on renal outcomes. Telmisartan, a 
lipophilic ARB with a long half-life, has been hypothesized to have a greater anti-proteinuric 
effect when compared to the shorter acting losartan. Therefore, the A comparison of telMisartan 
versus losArtan in hypertensive type 2 DiabEtic patients with Overt nephropathy (AMADEO) 
trial sought to investigate renal and cardiovascular endpoints. In this review, we discuss the 
pathophysiology of diabetic kidney disease and implications of the AMADEO trial in the context 
of current understanding from recent outcome trials.
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Introduction
Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD)1 
and is a multifactorial combination of hemodynamic and metabolic abnormalities that 
collectively contribute to kidney damage resulting in proteinuria and reductions in 
glomerular ﬁ  ltration rate (GFR). Recent data support that proteinuria is a surrogate 
maker for cardiovascular risk and reductions in proteinuria correlate with declines in 
cardiovascular morbidity and mortality. Thereby, interventions that target blood pres-
sure control and proteinuria, speciﬁ  cally interruption of the renin-angiotensin system 
(RAS) with either angiotensin converting enzyme (ACE) inhibitors or angiotensin II 
receptor blockers (ARB), have been utilized in attenuating the progression of DKD.2 
Among available ARBs, telmisartan has been reported to have a greater lipophilic-
ity, longer half-life, and debatably the most consistent reductions in blood pressure. 
Therefore, investigators recently sought to compare telmisartan with losartan, which 
has less lipophilicity and a shorter duration of action, in patients who had overt DKD 
(urinary protein to creatinine ratio   700) in the A comparison of telMisartan versus 
losArtan in hypertensive type 2 DiabEtic patients with Overt nephropathy (AMADEO) 
trial. Investigators reported that telmisartan was superior to losartan in reducing 
proteinuria in hypertensive patients with DKD with relatively similar reductions in 
blood pressures. Further, the authors proposed that the superiority of telmisartan could Vascular Health and Risk Management 2009:5 130
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be due to its intrinsic peroxisome proliferator-activated 
receptor–gamma (PPAR-γ) agonist properties.
The incidence of DKD continues to increase in the US 
and globally. Understanding the mechanisms underlying the 
development of DKD is essential for establishing novel thera-
peutic strategies for the prevention or arrest of progressive 
disease. Herein, we will review some of these mechanisms 
as they relate to the AMADEO trial ﬁ  ndings.
Pathophysiology and markers 
of diabetic kidney disease
Evidence suggests that up to 44% of patients with diabetes 
mellitus develop DKD.3 Development of DKD is associated 
with progressive functional and structural changes in the 
basic kidney unit, ie, the nephron and glomerulus,4 affected 
via hemodynamic and metabolic pathways. Hemodynamic 
and metabolic factors contribute equally towards the devel-
opment of DKD, it is now clear that these processes are 
interlinked. Earlier stages of DKD include a hyperﬁ  ltration 
mechanism that occurs due to decreased resistance of both 
afferent and efferent arteriole. Afferent arteriole has greater 
decrease in resistance than its efferent counterpart. There is 
defective autoregulation of tone due to complex interaction 
of mediators including prostanoids, nitric oxide, reactive 
oxygen species (ROS), lipids, vascular endothelial growth 
factor (VEGF), transforming growth factor-beta 1 (TGF-β1), 
high glucose and the RAAS, speciﬁ  cally angiotensin II 
(Ang II). These hemodynamic changes and the defect in 
autoregulation allow an increased ﬁ  ltration of albumin at the 
level of the glomerulus. It has been shown that proteinuria 
can occur as a result of molecular and structural abnormali-
ties in the podocyte slit diaphragm within the glomerular 
epithelial cell.6,7 Ang II has been reported to be a primary 
mediator of loss of the slit-pore diaphragm. In addition 
to promoting glomerular nephrin depletion, Ang II also 
appears to have other actions that promote the development 
of proteinuria, including trophic effects on the kidney and 
increasing glomerular membrane pore size. This in turn 
promote structural changes like mesangial cell proliferation, 
thickening of basement membrane that further potentiate 
injury to podocytes.6 At the molecular level, hyperglycemia 
and proteins altered by high blood glucose such as Amadori 
products and advanced glycation end products (AGEs) are 
key players in the development of DKD. Evidence suggests 
that an increase in reactive oxygen species (ROS) forma-
tion induced by high glucose-mediated activation of the 
mitochondrial electron-transport chain is an early event 
in the development of diabetic complications. A variety 
of tissue growth factors and cytokines are then induced 
through complex signal transduction pathways involving 
protein kinase C (PKC), mitogen-activated protein kinases 
(MAPK), and the transcription factor NF-κB. High glucose, 
AGEs, and ROS act in concert to induce growth factors and 
cytokines. Particularly, tissue growth factors are important 
in the development of renal hypertrophy and accumulation 
of extracellular matrix components.
Activation of the renin-angiotensin-aldosterone system 
(RAAS) by hemodynamic changes, high glucose, mechanical 
stress, and proteinuria with an increase in local formation of 
Ang II contribute many of the pathophysiological changes 
associated with DKD (Figure 1). In fact, it has been shown 
that Ang II is involved in almost every pathophysiological 
process implicated in the development of DKD (hemody-
namic changes, hypertrophy, extracellular matrix accumu-
lation, growth factor/cytokine induction, ROS formation, 
podocyte damage, proteinuria, interstitial inﬂ  ammation, 
adverse effects on the balance between the ﬁ  brinolytic and 
thrombotic mechanisms).8 Therefore, interruption of the 
RAAS via inhibition of Ang II is an essential part of every 
therapeutic regimen in managing the patient with DKD.
Role of drugs blocking RAAS
RAAS inhibition is the mainstay of therapy in preventing 
the progression of DKD. In addition to normalization of 
systemic and glomerular hypertension, it is now clear that 
inhibition of the RAAS at various levels by the Ang II 
antagonists (ACE inhibitors and ARBs) have several 
renoprotective effects, including anti-inﬂ  ammatory and 
anti-ﬁ  brotic mechanisms.9 Addition of diuretics has been 
strongly recommended by KDOQI guidelines to achieve 
target blood pressures of   130 mmHg in cases of recalcitrant 
hypertension in DKD patients.10 The role for aldosterone 
antagonist (spironolactone), renin antagonist (aliskiren) and 
statins in prevention of metabolic derangements consequent 
to RAAS overactivity in DKD is emerging. In whole animal 
models, experiments to tease out the non-hemodynamic 
renoprotective effects of the RAAS antagonists included 
transgenic rats with a human AT1 receptor (AT1R) gene which 
overexpressed AT1R.11 These rats developed signiﬁ  cant albu-
minuria, podocyte effacement, progressive ﬁ  brosis, leading 
to focal segmental glomerulosclerosis (FSGS), which were 
independent of blood pressure and reversed by the blockade 
of Ang II. Aldosterone has been shown to cause kidney 
oxidative stress, inﬂ  ammation, ﬁ  brosis, and sclerosis. Shibata 
et al demonstrated that aldosterone infusions and high-salt 
diet, when administered to uninephrectomized normotensive Vascular Health and Risk Management 2009:5 131
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Sprague Dawley (SD) rats, led to glomerulosclerosis, 
hypertension, and kidney damage.12 Administration of the 
mineralocorticoid receptor (MR ) blocker (spironolactone) 
ameliorated and reversed the harmful effects of aldosterone. 
A recent study, Aliskiren in the EValuation of PrOteinuria 
In Diabetes (AVOID) Trial, showed that the addition of 
a renin inhibitor to an ARB in diabetic and hypertensive 
patients decreases proteinuria further when compared with an 
ARB alone.13 Statins have been proposed to have pleiotropic 
effects, actions independent of their cholesterol-lowering 
mechanism. These include decreased ROS generation via 
inhibition of NADPH oxidase and therefore have a role as 
renoprotective agent.14 Large randomized controlled trials 
designed to target DKD populations may be able to provide 
comprehensive answers as to the usefulness of these drugs.
Strong evidence points to the expression of all RAAS 
components in the kidneys, including the podocytes and 
tubular cells.15 High glucose stimulates expression of renin 
and angiotensinogen in mesangial and tubular cells. This 
stimulation results in an increase in local Ang II concentra-
tions which may, in turn, through autocrine and paracrine 
pathways induce several cytokines and growth factors. 
Therefore blockade of the overexpressed RAAS will lead 
to renoprotection. Taking into account the many effects of 
the RAAS in the pathophysiology of DKD, early treatment 
with drugs interfering with the tissue effects of RAAS are a 
necessary prerequisite to prevent development and progres-
sion of DKD.16
Lessons from clinical trials 
on RAAS-blockade
Blockade of the RAAS is pivotal in the management of 
DKD as described above. Strong evidence favors the use of 
ACE inhibitors and ARBs in patients with type 2 diabetes 
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Figure 1 Schematic showing the current understanding of important players and pathways contributing to diabetic nephropathy/diabetic kidney disease. Point of action for 
telmisartan with dual ARB plus selective PPAR-γ agonist properties is highlighted. Positive indicates action favoring DKD and negative indicates protection against DKD.Vascular Health and Risk Management 2009:5 132
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Table 1 Recent clinical trials leading up to the AMADEO study
Trial/year Patient population N Treatment arms Primary endpoint Final outcome
HOPE19 2001 High-risk patients 
without known diabetes
5720 Ramipril/placebo New onset overt 
nephropathy
22% Reduction in new onset overt 
nephropathy (RR 0.66; 95% 
CI 0.51–0.85; p   0.001).
IDNT20 2001 Hypertension with 
diabetic nephropathy
1715 Irbesartan/amlodipine/
placebo
Composite of 
development of ESRD, 
doubling Cr.
Irbesartan signiﬁ  cantly reduced 
primary composite end point 
by 20% compared to placebo 
(p   0.02) and by 23% compared to 
amlodipine (p   0.006).
IRMA222 2001 Type 2 diabetes with MA 590 Irbesartan/placebo Time to onset of diabetic 
nephropathy
Irbesartan reduced risk of 
primary end point (HR 0.30; 
95% CI 0.14–0.61; p   0.001 for 
300 mg irbesartan; HR 0.61; 95% 
CI 0.34–0.99; p   0.08 for 150 mg 
irbesartan.
RENAAL23,24 2001 Type 2 diabetes with 
nephropathy
1513 Losartan/placebo Composite of doubling of 
Cr, development of ESRD.
Losartan signiﬁ  cantly reduced the 
composite end point by 16% 
(p   0.02), but not death.
MARVAL25 2002 Type 2 diabetes with MA 332 Valsartan/amlodipine % change in UAER from 
BL to 24 Wks.
UAER at 24 wk was reduced by 
44% with valsartan and 8% with 
amlodipine (p   0.001); valsartan 
signiﬁ  cantly reversed MA to normal 
albuminuria
BENEDICT26,27 2004 Type 2 diabetes and 
HTN but with normo-
albuminuria
1204 Trandalopril/
verapamil/placebo
Development of 
persistent MA
For developing end point 
AF = 0.39 for trandalopril + 
verapamil vs placebo. AF = 0.44 for 
trandalopril vs placebo and 
AF = 0.83 with verapamil vs 
placebo.
DETAIL29 2004 Type 2 diabetes with 
early nephropathy
250 Telmisartan/enalapril Change in the GFR 
(determined by measuring 
the plasma clearance of 
iohexol)
Change in the GFR was 
−17.9 mL/min/1.73 m2 of body-
surface area with telmisartan, as 
compared with −14.9 mL/min/1.73 m2 
with enalapril, for a treatment dif-
ference of −3.0 mL/min/1.73 m2 
(95 % CI −7.6–1.6 mL/ min/1.73 m2).
TRENDY30 2007 Type 2 diabetes, HTN, 
GFR   80 mL/min, and 
normo- or micro-
albuminuria.
96 Telmisartan/ramipril Increase in renal plasma 
ﬂ  ow (RPF)
Telmisartan increased RPF from 
652.0 ± 27.0 to 696.1 ± 
31.0 mL/min (p = 0.047), whereas 
ramipril produced no signiﬁ  cant 
changes in RPF. (r = 0.47, 
p   0.001).
INNOVATION32 
2007
Type 2 diabetes and 
UACR 100-300mg/g, 
Cr  1.5 mg/dl (men) 
and  1.3 mg/dl 
(women).
527 Telmisartan 
(80/40 mg)/placebo
Transition rate incipient 
to overt Nephropathy, 
UACR   300 mg/g, and 
increase   30% from 
baseline at 2 consecutive 
4-week visits.
Transition rates to overt 
nephropathy were 16.7% with 
80 mg telmisartan (n = 168), 22.6% 
with 40 mg telmisartan 
(n = 172), and 49.9% with placebo 
(n = 174) (both telmisartan doses/
placebo, p   0.0001).
VIVALDI31 2008 HTN SBP/
DBP   130/80 mmHg 
patients with type 2 
diabetes, proteinuria 
( 900 mg/24 h) and Cr 
( 3.0 mg/dL)
885 Telmisartan/valsartan Change from BL of 24 h 
proteinuria.
Comparable reduction in 24 h 
urinary protein excretion rates. 
Geometric mean reduction 
(95% conﬁ  dence interval) 
telmisartan, 33% (27%–39%); 
valsartan, 33% (27%–38%).
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and overt nephropathy.17 Current management consensus 
statements from the National Kidney Foundation (NKF)/
Kidney Disease Outcomes Quality Initiative (KDOQI),10 
American Diabetes Association (ADA),1 and Joint National 
Committee (JNC) VII18 advocate the use of ARBs for man-
agement of patients with hypertension and DKD, even in 
those with advanced stages of nephropathy as well as in those 
with microalbuminuria. ARBs have been shown to exert their 
beneﬁ  cial effect by blood pressure reduction, improving 
endothelial dysfunction and reducing oxidative stress.17
Data from the Heart Outcomes Prevention Evaluation 
(HOPE) Study evaluated microalbuminuria as a progressive 
manifestation of overt type nephropathy in patients with type 
2 diabetes as a secondary endpoint.19 Ramipril was shown 
to reduce the onset of overt nephropathy by 22%. Similar 
observations were reported in the Irbesartan type II Diabetic 
Nephropathy Trial (IDNT), irbesartan was superior to both 
placebo and amlodipine in improving time to the primary 
endpoint, which was the composite of doubling of baseline 
serum creatinine and development of ESRD.20 Interestingly, 
the beneﬁ  ts of irbesartan were seen with similar reductions 
in blood pressure when compared to amlodipine, revealing 
non-hemodynamic effects of ARBs. However, this trial did 
not include ACE inhibition in its treatment arms. Another 
caveat that was borne out of post-hoc analyses was that initial 
changes in proteinuria were not independent predictors of 
long-term renal outcomes, but were dependent on speciﬁ  c 
treatment arms (in this case irbesartan). This effect was later 
tested in the AMADEO trial. Analysis of IDNT showed that 
over a follow up period of 2.6 years there was a 2.2 times 
increase in risk of doubling serum creatinine or ESRD in 
patients with systolic blood pressure (SBP)   149 mmHg 
compared with those with SBP   143 mmHg regardless of 
the intervention used for treatment of blood pressure. Among 
the patients achieving comparable reduction in SBP, the 
incidence of renal endpoints was lower in patients treated 
with irbesartan compared to amlodipine.21
The Irbesartan in Patients with Type 2 Diabetes and 
Microalbuminuria Study (IRMA) further strengthened the 
results of IDNT by showing that irbesartan has a dose-
dependent improvement in time to onset of DKD.22 After a 
follow up of 2 years, it was found that only 5.2% patients 
treated with irbesartan 300 mg progressed to overt nephropa-
thy as opposed to 9.7% of those receiving irbesartan 150 mg 
and 14.9% of those receiving placebo. In fact, the IRMA 
study group hypothesized that the renoprotective effect of 
irbesartan was not fully evident in their original study due 
to dose limitations and they demonstrated even greater renal 
protection with 900 mg of irbesartan and minimal increase 
in side effects (IRMA-2). The Reduction of Endpoints in 
NIDDM with the Angiotensin II Antagonist Losartan Study 
(RENAAL) study was similar to the IDNT and IRMA studies 
and demonstrated delayed time to onset of renal dysfunction 
in the losartan treated group.23 Post hoc analyses of protein-
uria as secondary endpoint showed that early response to 
losartan therapy is an important predictor of long term renal 
protection.24 Both baseline and residual (6 month) albu-
minuria were linearly correlated with renal outcomes. The 
authors recommended reduction in albuminuria to the lowest 
achievable level as the optimum goal for therapy.
MicroAlbuminuria Reduction With VALsartan (MARVAL) 
Study targeted urine microalbumin excretion (UAER) as the 
primary endpoint and demonstrated reduction in albuminuria 
to 56% of its baseline in both normotensive and hypertensive 
Table 1 (Continued)
Trial/year Patient population N Treatment arms Primary endpoint Final outcome
ONTARGET28 2008 55 years or older with 
established atheroscle-
rotic vascular disease 
or with diabetes with 
end-organ damage
8542 Telmisartan/ramipril/
telmisartan + ramipril
Composite of dialysis, 
doubling of CR, and death
Composite primary outcome 
was similar for telmisartan (1147 
[13.4%]) and ramipril (1150 [13.5%]; 
HR 1.00, 95% CI 0.92−1.09), but 
was increased with combination 
therapy (1233 [14.5%]; HR 1.09, 
1.01−1.18, p = 0.037).
Abbreviations: BL, baseline; CI, conﬁ  dence interval; RR, relative risk; HR, hazard ratio; Cr, serum creatinine; CV, cardiovascular; HF, heart failure; CAD, coronary artery disease; 
MA, microalbuminuria; ESRD, end stage renal disease; RPF, renal plasma ﬂ  ow; MI, myocardial infarction; N, number of patients enrolled; UAER, urine albumin excretion; wk, 
weeks; GFR, glomerular ﬁ  lteration rate; NIDDM, non-insulin-dependent diabetes mellitus; HOPE, Heart Outcomes Prevention Evaluation study; IRMA, IRbesartan in patients 
with type 2 diabetes with MicroAlbuminuria study; IDNT, Irbesartan Diabetic Nephropathy Trial; LIFE, Losartan Intervention For Endpoint reduction in hypertension Study; 
MARVAL, MicroAlbuminuria Reduction with VALsartan trial; RENAAL, Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist; Losartan; BENEDICT, Bergamo 
Nephrologic Diabetes Complications Trial; TRENDY, Telmisartan versus Ramipril in renal Endothelial Dysfunction; INNOVATION, INcipieNt to OVert: Angiotensin II receptor 
blocker, Telmisartan, Investigation On type 2 diabetic Nephropathy; VIVALDI, inVestIgate the efﬁ  cacy of telmIsartan versus VALsartan in hypertensive type 2 DIabetic patients 
with overt nephropathy; ONTARGET, ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial.Vascular Health and Risk Management 2009:5 134
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type 2 diabetics after 6 months of intention to treat therapy.25 
Importantly, the improvement in albuminuria was independent 
of blood pressure, as the amlodipine treatment arm achieved 
similar reductions in blood pressure, once again demonstrating 
non-hemodynamic effects of ARBs in modulating pathophysi-
ology of DKD.
The Bergamo Nephrologic Diabetes Complications 
Trial (BENEDICT) compared the efﬁ  cacy of ACE inhibitor 
trandalopril versus non-dihydropyridine calcium channel 
blocker verapamil versus trandalopril alone versus verapamil 
alone versus placebo in delaying the incidence of microalbu-
minuria in type 2 diabetics.26,27 The trandalopril containing 
arms demonstrated signiﬁ  cant delay in the development of 
microalbuminuria. Interestingly, ONTARGET evaluated the 
use of ACE inhibitor in prevention of early chronic kidney 
disease.28 RAAS control with ACE inhibitor has been shown 
to prevent the emergence of persistent microalbuminuria in 
patients with type 2 diabetes and apparently normal urinary 
albumin levels ( 20 μg/min).
The Diabetics Exposed to Telmisartan and EnalaprIL 
(DETAIL) study was among the ﬁ  rst studies to compare 
the efﬁ  cacy of long-acting telmisartan with ACE inhibitor 
enalapril.29 Although there was an initial advantage in slow-
ing down the decline in GFR with telmisartan, end of trial 
analyses could only demonstrate non-inferiority over enala-
pril. Based on the ﬁ  ndings of DETAIL, it may be argued that a 
more aggressive approach to renoprotection may be required 
in the long term.16 The recently published Telmisartan versus 
Ramipril in renal Endothelial DYsfunction (TRENDY) study 
provided the ﬁ  rst head-to-head comparison of an ARB and 
an ACE inhibitor on renal endothelial function.30 TRENDY 
was performed in 96 patients with type 2 diabetes who had 
mild-to-moderate hypertension (seated SBP/diastolic blood 
pressure [DBP] 140 to 180/90 to 110 mm Hg), normo- or 
microalbuminuria, and GFR   80 mL/minute/1.73 m2. 
Patients were randomized to either telmisartan 40 mg or 
ramipril 5 mg for 3 weeks, followed by telmisartan 80 mg 
or ramipril 10 mg for 6 weeks. Both telmisartan and ramipril 
improved nitric oxide activity (a measure of endothelial func-
tion), with a trend toward superiority of telmisartan. There 
was also a signiﬁ  cant decrease in urinary albumin excretion 
from 9.0 to 7.3 mg/24 hours with telmisartan (p = 0.022), 
whereas the change from baseline with ramipril was not 
signiﬁ  cant.
In the study to inVestIgate the efﬁ  cacy of telmIsartan 
versus VALsartan in hypertensive type 2 DIabetic patients 
with overt nephropathy (VIVALDI), both telmisartan and 
valsartan improved proteinuria by 33% at the end of  1 year.31 
However, the beneﬁ  ts from telmisartan were not signiﬁ  cantly 
greater than valsartan in this intention to treat analysis. The 
authors did note that patients in the valsartan treatment arm 
tended to receive additional antihypertensives in a greater 
proportion than the telmisartan group most probably due 
to the shorter half-life of the former drug.31 Moreover, pro-
teinuria measurements were based on 24-hour urine protein 
collections. The INcipieNt to OVert: Angiotensin II recep-
tor blocker, Telmisartan, Investigation On type 2 diabetic 
Nephropathy (INNOVATION) trial showed that telmisartan 
is able to prevent the transition to overt renal disease in 
Japanese patients after a mean follow-up of 1.3 years.32 The 
relative risk of transition to overt nephropathy was reduced 
by 66% and 55%, respectively, with telmisartan 80 mg and 
telmisartan 40 mg compared with placebo in the overall 
patient population. Thus, for every 3 patients treated, telmis-
artan 80 mg prevented 1 transition to overt nephropathy 
over the course of approximately 1 year. The renoprotective 
beneﬁ  t of telmisartan was also apparent in patients who were 
normotensive at baseline, which suggests that there is a blood 
pressure-independent effect. In addition, INNOVATION 
showed treatment of patients with telmisartan could bring 
about regression of incipient disease, with 21.2% and 
12.8% of patients in the telmisartan 80 mg and 40 mg arms 
respectively, becoming normoalbuminuric compared with 
1.2% of patients receiving placebo (both doses p   0.001).32 
Interestingly, both the DROP trial and the IRMA-2 substudy 
demonstrated a greater anti-proteinuric effect with ultra-high 
doses of ARBs while not signiﬁ  cantly achieving any further 
lowering in blood pressure.33,34,35
The recently published ONgoing Telmisartan Alone 
and in combination with Ramipril Global Endpoint Trial 
(ONTARGET trial) compared the renal effects of ramipril 
(an ACE inhibitor), telmisartan (an ARB), and their com-
bination in patients aged 55 years or older with established 
atherosclerotic vascular disease or diabetes with end-organ 
damage.28 The number of events for the composite primary 
outcome dialysis, doubling of serum creatinine, and death 
were similar for telmisartan and ramipril but was increased 
with combination therapy. The secondary renal outcome, 
dialysis or doubling of serum creatinine, was similar for 
telmisartan and ramipril and more frequent with combination 
therapy. The trial authors concluded that in people at high 
vascular risk, telmisartan’s effects on major renal outcomes 
are similar and non-inferior to those of ramipril. Although 
combination therapy reduced proteinuria to a greater extent 
than monotherapy, the net effect on renal outcomes was 
opposite. The take-home message was that, proteinuria by Vascular Health and Risk Management 2009:5 135
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itself cannot be taken as a deﬁ  nitive marker of improved renal 
function, and that the beneﬁ  ts of any treatment, including 
combination blockade of the RAS on major renal outcomes, 
remain to be elucidated.
Rationale for AMADEO trial
Substantial evidence has accumulated over the last decade 
in favor of using RAAS inhibitors for slowing down the 
progression and onset of DKD. Use of ARB and ACE 
inhibition is clearly superior to the use of non-RAAS blood 
pressure control medications in ameliorating renal damage 
at similar levels of blood pressure control.20 This may be due 
to the non-hemodynamic and metabolic improvements in 
the cardiovascular system including better endothelial func-
tion, reduced oxidative stress, decrease in inﬂ  ammation and 
ﬁ  brosis. Evidence has emerged demonstrating that a  30% 
reduction in proteinuria at 6 months to 1 year following ini-
tiation of treatment was associated with slower progression 
of DKD and a reduction in the incidence of cardiovascular 
events, independent of reductions in blood pressures. The 
ARBs have been shown to be non-inferior to ACE inhibi-
tors in achieving blood pressure control and reductions in 
proteinuria, often leading to interchangeable regimens based 
on these drugs depending on the tolerability by patients.
Telmisartan, an ARB with high lipophilicity, a high level 
of angiotensin II type-1 (AT1) receptor (AT1R) binding and 
a long half-life is currently FDA approved for the treatment 
of hypertension but is not indicated yet for the treatment 
of proteinuria in patients with diabetes. Instead, losartan 
is currently approved as a ﬁ  rst-line treatment for DKD. 
Telmisartan has been reported to achieve smoother blood 
pressure control with fewer side effects when compared to 
other ARBs. In addition, animal experiments have demon-
strated other potential mechanisms for its beneﬁ  cial effects 
including PPAR-γ agonist properties.36 All of these properties 
together may make telmisartan an ideal drug to achieve the 
target of   30% reduction in proteinuria ultimately resulting 
in a slower progression to kidney failure.
Pharmacology of telmisartan
Telmisartan is a potent, long-lasting, non-peptide antagonist 
of the AT1R. It selectively and insurmountably inhibits 
stimulation of the AT1 receptor by angiotensin II without 
affecting other receptor systems involved in cardiovascular 
regulation. Very high lipophilicity, a unique feature of telmis-
artan, coupled with a high volume of distribution; indicate 
that the compound offers a clinically important advantage of 
good tissue penetration (Table 2). Due to its physicochemical 
properties, telmisartan shows excellent oral absorption and 
tissue penetration.38
Afﬁ  nity for AT1 receptor
Studies have demonstrated that telmisartan has the stron-
gest binding afﬁ  nity to AT1 receptor among various ARBs 
(Table 2). The rank order of afﬁ  nity is in the following order; 
telmisartan   olmesartan   candesartan   EXP3174   
valsartan   losartan.39 The ﬁ  ndings of AMADEO suggest 
that telmisartan may have long-lasting blood pressure-low-
ering effects and superior cardioprotective properties in 
patients with hypertension due to its strong AT1 receptor 
antagonistic ability.
Pharmacokinetics
Telmisartan is not a pro-drug and has a longer terminal 
elimination half-life than other commercially available 
sartans (∼24 hours), making it suitable for once-daily 
dosing. The compound is not metabolized by cytochrome 
P450 isoenzymes and has a low risk for P450-based drug 
interactions.37,38 A relevant fact to be noted is that unlike 
other ARBs, where up to 50% of the dose is excreted by 
the kidney, only 1% of a telmisartan dose in excreted 
by the kidney. Therefore renal impairment is unlikely to 
affect the pharmacokinetics of telmisartan.37 Telmisartan 
has a pharmacokinetic proﬁ  le that allows differentiating 
it from other angiotensin receptor blockers; long duration 
of action (mean terminal half-life of 24 hours, the longest 
in its class) and high tissue penetration (illustrated by the 
Table 2 Pharmacokinetics of ARBs37,38,39
Drug Bioavailability (%) Half-life (hours) Lipophilicity (log P)a Protein binding (%) AT1 receptor afﬁ  nity
Losartan 33 2 (6–9) −2.45 98.7 20 nmol/L
Valsartan 25 9 −0.95 95 1.3 nmol/L
Irbesartan 70 11–15 +1.48 90 2.7 nmol/L
Telmisartan 43 24 +1.48  99 3.7 nmol/L
Eprosartan 15 5–7 – 98 1.4–3.9 nmol/L
aThe logarithm of the ratio of the concentrations of the un-ionized solute in the solvents is called log P (partition coefﬁ  cient).Vascular Health and Risk Management 2009:5 136
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highest volume of distribution in its class), and high afﬁ  nity 
for angiotensin receptor.
PPAR-γ agonist effect of telmisartan
Telmisartan is the only ARB which acts as a partial agonist 
of PPAR-γ. PPAR-γ is a ligand activated transcription factor 
that regulates cell growth, inﬂ  ammation, lipid metabolism 
and insulin sensitivity. It has been successfully shown that 
PPAR-γ agonists limit high glucose-induced inﬂ  ammation in 
proximal tubular cells (PTC).40 PPAR-γ agonists also exert 
anti-ﬁ  brotic effects in human proximal tubular cells under 
high glucose conditions by attenuating the increase in AP-1, 
TGF-β1 and downstream production of the extracellular 
matrix protein, ﬁ  bronectin. PPAR-γ agonists can improve 
insulin sensitivity, reduce triglyceride levels and decrease 
the risk of atherosclerosis.
A study examined the ability of different ARBs to 
activate PPAR-γ in a cell-based transient transfection assay 
(Figure 2). This assay was designed to eliminate interfer-
ence from endogenous nuclear receptors. In the results 
shown here, each ARB was used at a concentration of 
10 mmol/L. Telmisartan was the only ARB to show strong 
(27-fold) activation, although irbesartan also showed a 
slight activation (2- to 3-fold). By comparison, full PPAR-γ 
agonists show ∼140-fold activation in this assay. Importantly, 
telmisartan was also the only ARB that activated PPAR-γ 
when tested at lower concentrations that can be achieved 
physiologically (1–5 mmol/L). Telmisartan therefore acts 
as a partial agonist of PPAR-γ.36
There have been reports of sodium and ﬂ  uid retention 
associated with full PPAR-γ agonist activity. Evidence 
suggests that PPAR-γ is highly expressed in the medullary 
collecting ducts with lower expression levels in glomeruli, 
proximal tubules and microvasculature and is a major site for 
increased ﬂ  uid reabsorption in response to PPAR-γ agonist 
activity.41,42 In these collecting ducts, PPAR-γ activation 
increases sodium re-absorption through epithelial sodium 
channel (ENaC) dependent and independent mechanisms 
(Na+-K+-ATPase system). Guan et al showed that showed 
that mice treated with thiazolidinediones (TZDs, full 
PPAR-γ agonists), experience early weight gain from 
increased total body water.41 Weight gain was blocked by 
the collecting duct-speciﬁ  c diuretic amiloride and was also 
prevented by deletion of PPAR-γ from the collecting duct, 
using PPAR-γ (ﬂ  ox/ﬂ  ox) mice. Moreover, treating cultured 
medullary collecting ducts with TZD increased amiloride-
sensitive sodium absorption and mRNA expression of 
ENaC-γ isoform through a PPAR-γ dependent pathway. 
Furthermore, in the blood vessels of adipose tissues, PPAR-γ 
ligands activate protein kinase C (PKC), vascular endothelial 
growth factor (VEGF), and nitric oxide (NO), which together 
lead to increased endothelial permeability. Thus increased 
renal sodium retention at the level of the collecting duct in 
conjunction with increased vascular permeability may cause 
edema development and account for the side effects of drugs 
with full PPAR-γ agonist activity.
The above-mentioned adverse effects have caused high 
attrition rates which led to the need for the discovery and 
characterization of alternative PPAR modulators that would 
retain the beneﬁ  cial properties of these drugs while avoiding 
the cardiovascular side effects. These are called the Selective 
Modulators of PPAR-γ activity (SPPARγM).43,46 PPAR-γ 
receptor is a multivalent receptor whose ligand binding 
domain can accommodate different ligands (full agonist, 
partial agonist, or SPPARγM) and is capable of inducing 
distinct receptor combinations leading to selective gene 
expression. Each ligand–receptor complex assumes a some-
what different three-dimensional conformation, leading to 
unique and differential interactions with co-factors, histones, 
and other transcription factors. Consequently, each PPAR-γ 
ligand-receptor complex leads to a differential, but overlap-
ping, pattern of gene expression and ultimately differential 
biological responses.43,46 Telmisartan has been shown to be a 
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partial PPAR-γ agonist and may have SPPARγMs properties 
as well.43 Schupp et al used diet-induced obese mouse models 
and analysis of PPAR-γ protein conformation using protease 
protection to show that telmisartan directly interacts with the 
receptor, producing distinct conformational change compared 
with a TZD.43 Telmisartan signiﬁ  cantly reduced fasting 
plasma insulin and glucose levels and improved glucose 
tolerance and insulin sensitivity and caused signiﬁ  cantly less 
weight gain compared with mice treated with pioglitazone. 
In vivo studies therefore suggest that Telmisartan has the 
beneﬁ  cial properties of PPAR-γ agonists sans the side effects 
including sodium retention, peripheral edema and weight 
gain exhibited by some of the other full PPAR-γ agonists. 
The safety proﬁ  le may imply an important use for drugs like 
telmisartan in the treatment of metabolic syndrome.45
AMADEO trial2
In the AMADEO trial, diabetic patients fulﬁ  lling the inclu-
sion criteria were prospectively randomized (double-blind, 
double-dummy, forced titration) to receive telmisartan (n = 419) 
or losartan (n = 441), following a 2-month drug-free wash-
out period. Patients were treated for 52 weeks in a forced-
titration dosing, reaching maximum doses of 100 mg/day 
losartan and 80 mg/day telmisartan. Add on therapy with 
other antihypertensive medications were provided in case 
SBP remained  130 mmHg and DBP   80 mmHg after 
forced titration of the study drugs. The two study arms did 
not have signiﬁ  cant differences in the use of adjunctive 
therapy. A drug-free follow up group included 346 patients 
for 2 months after the trial was concluded.
After a 4-week run-in period, 860 hypertensive patients 
(BP  130/80 mmHg) with type 2 diabetes and overt 
nephropathy (UPC   700 mg/g) were randomized to 
one of two treatment arms: telmisartan 40 mg or losartan 
50 mg. After 2 weeks, the doses were increased to 80 mg 
and 100 mg, respectively. If blood-pressure control was not 
at goal, 25 mg of hydrochlorothiazide (HCTZ) was added, 
and if blood pressure was still resistant, clinicians were free 
to add a calcium-channel blocker. Baseline characteristics 
between the two treatment arms were not statistically differ-
ent. After one year of therapy with the two ARBs, telmisartan 
provided greater reductions in the amount of protein in the 
urine (Table 3A), a ﬁ  nding not attributed to blood-pressure 
control, as reductions in SBP and DPB were similar in both 
treatment arms. As per study protocol, after a 2-month period 
at study completion in which both drugs were stopped, inves-
tigators reported a sustained and persistent antiproteinuric 
effect with the novel ARB, telmisartan. The persistent effect 
of telmisartan was surprising and the authors suggest that 
this beneﬁ  cial effect could be explained by differences in 
receptor bindings, duration of action, or lipophilicity between 
the two drugs used in the trial. The difference in secondary 
end points of serum creatinine, eGFR, serum aldosterone 
and CRP failed to reach signiﬁ  cance (Table 3B). Serum 
aldosterone tended to decrease to a greater extent in the 
telmisartan group, however statistical signiﬁ  cance could not 
be attained (p = 0.07).
Does AMADEO trial unequivocally 
prove superiority of telmisartan?
Based on the AMADEO trial, a telmisartan-based regi-
men provides for robust anti-proteinuric effect in type 2 
diabetic patients with hypertension and overt nephropathy. 
This anti-proteinuric effect is greater than a losartan-based 
regimen at levels of blood pressure that were not signiﬁ  cantly 
different between groups and is attributed to greater lipophilic-
ity and longer duration of action of this drug. Based on avail-
able trial data, this difference in anti-proteinuric effect may 
translate into better cardiovascular and renal outcomes.
The contribution of confounding factors to telmisartan’s 
superiority over losartan remain unclear, especially telmis-
artan’s partial PPAR-γ agonist effect. As discussed above, 
PPAR-γ agonists limit high glucose-induced inﬂ  ammation 
in proximal tubular cells, exert anti-ﬁ  brotic effects in the 
same cells by attenuating the increase in AP-1, TGF-β1 
Table 3A Primary endpoint of AMADEO trial2
Primary endpoint Telmisartan Losartan P value
Urine protein: creatinine 0.71 0.80 0.0284
Table 3B Secondary endpoint of AMADEO trial2
Secondary endpoint Telmisartan 80 mg Losartan 100 mg P value
Serum creatinine 15% (12% to 18%) 15% (12% to 18%) 0.895
eGFR −6.49 (–7.56 to 5.42) −6.50 (−7.56% to −5.43) 0.9913
Serum aldosterone −23 (–29% to 18%) −17% (–23% to −11%) 0.0746
CRP −6 (–15% to 4%) 1% (−9% to 13%) 0.277
Abbreviations: CRP, C-reative protein; eGFR, estimated glomerular ﬁ  ltration rate.Vascular Health and Risk Management 2009:5 138
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and the downstream production of the extracellular matrix 
protein ﬁ  bronectin and have been shown to improve insulin 
sensitivity, reduce triglyceride levels and decrease the risk 
for atherosclerosis. This has been acknowledged by the 
trial authors as an explanation for telmisartan’s mechanism 
of action in vitro and further studies need to be done to 
demonstrate the action in vivo. Another issue regarding 
the differences in proteinuria between the groups may 
relate to a lower blood pressure favoring one group. The 
trial showed that blood pressure was decreased equally in 
both groups although not as much as the Captopril Study 
Group (CSG) (∼3 mmHg in AMADEO versus ∼4 mmHg 
in CSG). In addition, the telmisartan group separated itself 
from the losartan group at day 56 by 4.2 mmHg, although 
this difference was narrower at all other time-points. In the 
context that the study may be underpowered to detect 
differences in BP between groups, the authors concluded 
that the blood pressure differences were not statistically 
signiﬁ  cant and larger well-designed trials were needed to 
detect the effects of such small blood pressure differences 
on proteinuria. An important observation is that both the 
treatment arms did not have signiﬁ  cant side effects but there 
was a 20% dropout rate for the trial which was consistent 
in both the arms. Clariﬁ  cation regarding the reasons for the 
dropouts was not outlined in the published trial and could 
be important in the ﬁ  nal analysis. Another factor that could 
have affected proteinuria is a disproportionate increase in 
dietary sodium intake in one group, since this is known to 
blunt the antiproteinuric effects of the ARB. However, the 
study detected no differences between groups in sodium 
excretion.
Analysis of the secondary endpoints of AMADEO trial 
brings forth an interesting trend. Serum aldosterone is an 
important part of RAAS and evidence points to some of the 
downstream effects of Ang II are mediated via release of 
aldosterone. Although not statistically signiﬁ  cant, the study 
detected a trend towards greater reductions in aldosterone 
in the telmisartan group when compared to the losartan 
group (p = 0.07). The signiﬁ  cance of this interesting trend 
is not clear at this point. However, future studies aimed at 
dissecting the role of telmisartan in ameliorating aldosterone-
mediated DKD may answer this question.
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Recent data from the VIVALDI trial (as described above) 
compared the renoprotective effects of telmisartan versus 
valsartan and found that they had comparable renoprotec-
tive effects.31 In other words, telmisartan was shown to be 
non-inferior at best to valsartan in slowing the progression 
of DKD. These ﬁ  ndings were in contrast to the ﬁ  ndings of 
the AMADEO trial. There are several possible explanations 
for the discrepant results including the methodology used 
to measure the primary endpoint; urine protein to creati-
nine ratio in the AMADEO trial as compared to a 24-hour 
urine protein used in VIVALDI trial. Furthermore, in the 
VIVALDI trial, participants in the valsartan group required 
additional antihypertensives more frequently than the 
telmisartan group to achieve similar levels of blood pressure 
control. As described above, this important confounding 
factor was eliminated in the AMADEO trial where none 
of the treatment arms was favored with better blood pres-
sure control.2 Lastly, the ethnicity of the participants in the 
VIVALDI trial was 80% Caucasian population compared 
to just 45% in the AMADEO trial, the implications of this 
ethnic homogeneity in VIVALDI with respect to ﬁ  nal 
analysis, are unclear.
Role for aldosterone antagonism
An important question that arises out of AMADEO trial is 
the use of aldosterone inhibiting agents to decrease protein-
uria? Whole animal studies have suggested that aldosterone 
may contribute to oxidative stress, endothelial dysfunction 
and progressive kidney disease. Thereby, administra-
tion of selective and non-selective MR antagonists may 
provide additional renal beneﬁ  ts to the ACE inhibitors and 
ARBs.47 In a study published in 2004, Zhou et al showed 
that spironolactone may effectively reduce proteinuria in 
patients with CKD.47 Concerns remain with regard to the risk 
for hyperkalemia in patients with CKD, however. Prospec-
tive randomized trials are necessary to conﬁ  rm the efﬁ  cacy 
and safety of antagonists of aldosterone on proteinuria and 
progression of CKD.
Conclusions
Data from the AMADEO trial demonstrate the superiority 
and/or non-inferiority of telmisartan as a renoprotective agent 
when compared to losartan, an already established ARB in 
the treatment of DKD. The superiority as outlined is based 
on the unique mechanism of action of this ARB and the 
pharmacokinetics which seem to be extremely favorable and 
ideal for treating DKD. As data from recent clinical trials 
are emerging, use of proteinuria as a surrogate marker of 
renal protection is being strongly questioned. However, until 
additional means of measuring kidney damage on a large 
scale are available, this endpoint may not have been meaning-
fully tested. Additional questions arise due to some confound-
ing factors in this study but the overwhelming evidence does 
uphold the superiority of telmisartan. Lastly, the secondary 
endpoint of the study does suggest a renoprotective role for 
aldosterone in DKD and we need well-designed randomized 
trials for aldosterone antagonists like spironolactone.
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